Back to top
more

TG Therapeutics (TGTX)

(Real Time Quote from BATS)

$29.88 USD

29.88
5,900,987

-5.14 (-14.68%)

Updated Aug 4, 2025 11:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Zacks Equity Research

Will TG Therapeutics (TGTX) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Bio-Rad Laboratories (BIO) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 5.80% and 0.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zimmer Biomet (ZBH) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 2.33% and 0.57%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Does TG Therapeutics (TGTX) Have the Potential to Rally 127.76% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 127.8% in TG Therapeutics (TGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Bio-Rad Laboratories (BIO) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of -18.82% and 8.47%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Neogen (NEOG) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of -21.43% and 1.23%, respectively, for the quarter ended August 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Do Options Traders Know Something About TG Therapeutics (TGTX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to TG Therapeutics (TGTX) stock based on the movements in the options market lately.

Zacks Equity Research

TG Therapeutics (TGTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -30.77% and 15.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

InMode (INMD) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

InMode (INMD) is expected to report strong Q2 consumable and service revenues, banking on strong performances of seven patented technologies across 10 product families.

Zacks Equity Research

What's in Store for Canopy Growth (CGC) in Q1 Earnings?

by Zacks Equity Research

Strong demand for legal cannabis products in the Canadian recreational cannabis market and the launch of new products are expected to have driven Canopy Growth's (CGC) Q1 performance.

Zacks Equity Research

Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?

by Zacks Equity Research

Zimmer Biomet (ZBH) is expected to have witnessed procedure recovery in its legacy business in the second quarter.

Zacks Equity Research

Breast Health Arm to Boost Hologic (HOLX) in Q3 Earnings

by Zacks Equity Research

Hologic's (HOLX) Breast Health is likely to have driven Q3 performance, owing to strong performance from improved semiconductor chip availability and strong backlog.

Zacks Equity Research

Down -12.63% in 4 Weeks, Here's Why You Should You Buy the Dip in TG Therapeutics (TGTX)

by Zacks Equity Research

The heavy selling pressure might have exhausted for TG Therapeutics (TGTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

The growing adoption of Panther instruments and an expanded Panther installed base as well as strength in Breast Health is expected to have driven Hologic's (HOLX) Q3 revenues.

Zacks Equity Research

Will Boston Scientific (BSX) Beat Q2 Earnings Estimates?

by Zacks Equity Research

Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN and other interventional cardiology therapies.

Zacks Equity Research

LabCorp (LH) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Sales rebound in the base business for Diagnostics business and strong drug development orders are expected to have driven LabCorp's (LH) second-quarter performance.

Zacks Equity Research

What's in Store for Edwards Lifesciences (EW) in Q2 Earnings?

by Zacks Equity Research

Within the Transcatheter Aortic Valve Replacement (TAVR) arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in TAVR procedures globally.

Zacks Equity Research

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Zacks Equity Research

Quanterix Corporation (QTRX) Surges 13.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Zacks Equity Research

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Zacks Equity Research

TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

TG Therapeutics (TGTX) delivered earnings and revenue surprises of 22.22% and 105.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TG Therapeutics (TGTX) Surges 22.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

TG Therapeutics (TGTX) closed at $15.48 in the latest trading session, marking a -1.46% move from the prior day.